SCHEMBL7344711

SCHEMBL7344711

COc1ccc2ccc(C(=N)N)c(OS(C)(=O)=O)c2c1-c1ccoc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 6/20 0.53
F2 P00734 2/20 0.53
PLG P00747 2/20 0.53
KLK1 P06870 2/20 0.53
PRSS1 P07477 2/20 0.53
PLAT P00750 1/20 0.53
FYN P06241 1/20 0.32
ERN1 O75460 1/20 0.32
PDGFRB P09619 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
POLB P06746 1/20 0.30
MAPT P10636 1/20 0.30
PKM P14618 1/20 0.30
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30
BLM P54132 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7334930 0.78 MAPT (0.37) PLAUF2PLGKLK1PRSS1
SCHEMBL7344706 0.73 PLAU (0.87) PLAUF2PLGKLK1PRSS1
SCHEMBL7338292 0.71 F2 (0.55) PLAUF2PLGKLK1PRSS1
SCHEMBL7341864 0.67 PLAU (0.58) PLAUF2PLGKLK1PRSS1
SCHEMBL7337655 0.63 PLAU (0.50) PLAUF2PLGKLK1PRSS1
SCHEMBL26260067 0.62 F2 (0.58) PLAUF2PLGKLK1PRSS1
SCHEMBL7623314 0.61 F2 (0.31) PLAUF2PLGKLK1PRSS1
SCHEMBL1133134 0.61 F2 (0.49) PLAUF2PLGKLK1PRSS1
SCHEMBL28104077 0.61 MAPT (0.46) PLAUPRSS1MEN1ALDH1A1LMNA
SCHEMBL22291213 0.61 PRSS1 (0.43) PLAUF2PLGKLK1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885F2 38/4885PLG 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.